Aripiprazole combined with other psychotropic drugs in pregnancy: two case reports.
Maternal exposure to second generation antipsychotics during pregnancy has been associated with some negative effects for both mothers and infants. Aripiprazole is becoming more readily used, although data regarding its use in pregnancy are limited. Additionally there are limited data with regards to the impact of polypharmacy on pregnancy outcomes. Given the relative paucity of information related to aripiprazole use in pregnancy it is difficult to counsel women on potential risks or side effects. We present two cases that illustrate the use of aripiprazole as a part of a polypharmacy regimen in pregnancy and describe the pregnancy outcomes in an effort to help clinicians facing complex treatment decisions in pregnancy.
Insight Behavioral Health Centers and Women's Mental Health, University of Illinois at Chicago, Chicago, Illinois, U.S.A.
Vesna
V
Pirec
General Adult and Reproductive Psychiatrist, Chicago, Illinois, U.S.A.
Aarti
A
Mehta
Women's Mental Health and Women's Mental Health Fellowship,University of Illinois at Chicago, Chicago, Illinois, U.S.A.
Sittanur
S
Shoush
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects*; D018692:Antimanic Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D000068180:Aripiprazole / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced*; D019338:Polypharmacy; D011247:Pregnancy; D055815:Young Adult
D000927:Anticonvulsants; D018692:Antimanic Agents; D014150:Antipsychotic Agents; D000068180:Aripiprazole